$ERNA
Eterna Therapeutics Inc.

2024 Q2 Form 10-Q Financial Statement

#000114036124026010 Filed on May 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $47.00K $47.00K
YoY Change
Cost Of Revenue $95.00K $61.00K
YoY Change 22.0%
Gross Profit -$48.00K -$14.00K
YoY Change -72.0%
Gross Profit Margin -102.13% -29.79%
Selling, General & Admin $3.896M $4.315M
YoY Change 55.22% 20.19%
% of Gross Profit
Research & Development $987.0K $1.458M
YoY Change -37.49% -12.9%
% of Gross Profit
Depreciation & Amortization $44.00K $39.00K
YoY Change 120.0% 85.71%
% of Gross Profit
Operating Expenses $4.883M $5.773M
YoY Change 7.34% 8.6%
Operating Profit -$4.931M -$5.787M
YoY Change 8.4% 8.86%
Interest Expense -$797.0K -$786.0K
YoY Change -4085.0% 1472.0%
% of Operating Profit
Other Income/Expense, Net -$595.0K -$856.0K
YoY Change -1422.22% 801.05%
Pretax Income -$5.526M -$6.643M
YoY Change 22.69% 22.77%
Income Tax $3.000K $4.000K
% Of Pretax Income
Net Earnings -$5.500M -$6.600M
YoY Change 22.01% 22.22%
Net Earnings / Revenue -11702.13% -14042.55%
Basic Earnings Per Share -$1.02 -$1.23
Diluted Earnings Per Share -$1.02 -$1.23
COMMON SHARES
Basic Shares Outstanding 5.410M 5.410M
Diluted Shares Outstanding 5.410M shares 5.410M

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.586M $5.116M
YoY Change 40.54% -5.26%
Cash & Equivalents $2.586M $5.116M
Short-Term Investments
Other Short-Term Assets $769.0K $697.0K
YoY Change -28.13% 48.3%
Inventory
Prepaid Expenses
Receivables $228.0K $351.0K
Other Receivables $228.0K $351.0K
Total Short-Term Assets $3.583M $6.164M
YoY Change -7.92% -5.39%
LONG-TERM ASSETS
Property, Plant & Equipment $654.0K $710.0K
YoY Change 238.86% 230.23%
Goodwill $2.000M $2.000M
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $120.0K $120.0K
YoY Change -91.27% -90.34%
Total Long-Term Assets $42.90M $43.49M
YoY Change -0.37% 406.14%
TOTAL ASSETS
Total Short-Term Assets $3.583M $6.164M
Total Long-Term Assets $42.90M $43.49M
Total Assets $46.49M $49.66M
YoY Change -1.0% 228.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.193M $2.063M
YoY Change -18.02% 41.2%
Accrued Expenses $2.389M $1.868M
YoY Change 13.28% -7.16%
Deferred Revenue
YoY Change
Short-Term Debt $225.0K $768.0K
YoY Change -87.14% -56.11%
Long-Term Debt Due $331.0K
YoY Change
Total Short-Term Liabilities $9.600M $7.768M
YoY Change 33.98% 43.69%
LONG-TERM LIABILITIES
Long-Term Debt $8.895M $8.014M
YoY Change 2595.45% 940.78%
Other Long-Term Liabilities $84.00K $84.00K
YoY Change -99.76% -3.45%
Total Long-Term Liabilities $84.00K $84.00K
YoY Change -99.77% -3.45%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.600M $7.768M
Total Long-Term Liabilities $84.00K $84.00K
Total Liabilities $55.01M $53.07M
YoY Change 27.67% 586.71%
SHAREHOLDERS EQUITY
Retained Earnings -$199.2M -$193.6M
YoY Change 13.7% 13.42%
Common Stock $27.00K $27.00K
YoY Change 0.0% 3.85%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$8.526M -$3.412M
YoY Change
Total Liabilities & Shareholders Equity $46.49M $49.66M
YoY Change -1.0% 228.68%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$5.500M -$6.600M
YoY Change 22.01% 22.22%
Depreciation, Depletion And Amortization $44.00K $39.00K
YoY Change 120.0% 85.71%
Cash From Operating Activities -$2.259M -$3.700M
YoY Change -41.63% -38.33%
INVESTING ACTIVITIES
Capital Expenditures $249.0K $101.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $4.000K
YoY Change
Cash From Investing Activities -$249.0K -$97.00K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -22.00K 1.385M
YoY Change -107.1%
NET CHANGE
Cash From Operating Activities -2.259M -3.700M
Cash From Investing Activities -249.0K -97.00K
Cash From Financing Activities -22.00K 1.385M
Net Change In Cash -2.530M -2.412M
YoY Change -28.93% -59.8%
FREE CASH FLOW
Cash From Operating Activities -$2.259M -$3.700M
Capital Expenditures $249.0K $101.0K
Free Cash Flow -$2.508M -$3.801M
YoY Change -35.19% -36.65%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Cash
Cash
7575000
CY2024Q1 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
351000
CY2023Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
425000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
697000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1599000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
6164000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
9599000
CY2024Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
4095000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
4095000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
710000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
493000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
36524000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
32781000
CY2023Q4 us-gaap Goodwill
Goodwill
2044000
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
120000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
120000
CY2024Q1 us-gaap Assets
Assets
49657000
CY2023Q4 us-gaap Assets
Assets
49132000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2063000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1067000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1868000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1893000
CY2024Q1 us-gaap Taxes Payable Current
TaxesPayableCurrent
6000
CY2023Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
2000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2874000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2216000
CY2024Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
189000
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
190000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
7768000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6573000
CY2023Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
6773000
CY2024Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
186000
CY2023Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
116000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
32854000
CY2024Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
345000
CY2023Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
392000
CY2024Q1 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
107000
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
107000
CY2024Q1 us-gaap Liabilities
Liabilities
53069000
CY2023Q4 us-gaap Liabilities
Liabilities
46899000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.005
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.005
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
156000
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
156000
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
156000
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
156000
CY2024Q1 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
156000
CY2023Q4 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
156000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.005
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.005
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
27000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
27000
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
190188000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
189186000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-193628000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-186981000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-3412000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
2233000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
49657000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
49132000
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000748592
CY2023Q4 us-gaap Other Liability Current Related Party Type Extensible Enumeration
OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2024Q1 us-gaap Other Liability Current Related Party Type Extensible Enumeration
OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-11460
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
Eterna Therapeutics Inc.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
31-1103425
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
1035 Cambridge Street, Suite 18A
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02141
CY2024Q1 dei City Area Code
CityAreaCode
212
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
582-1199
CY2024Q1 dei Security12b Title
Security12bTitle
Common stock, $0.005 par value per share
CY2024Q1 dei Trading Symbol
TradingSymbol
ERNA
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
5410331
CY2024Q1 us-gaap Cash
Cash
5116000
CY2024Q1 us-gaap Goodwill
Goodwill
2044000
CY2024Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
768000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1205000
CY2024Q1 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
8014000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
36565000
CY2024Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
84000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
84000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5410000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5410000
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5410000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5410000
CY2024Q1 us-gaap Revenues
Revenues
47000
CY2023Q1 us-gaap Revenues
Revenues
0
CY2024Q1 us-gaap Cost Of Revenue
CostOfRevenue
61000
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
50000
CY2024Q1 us-gaap Gross Profit
GrossProfit
-14000
CY2023Q1 us-gaap Gross Profit
GrossProfit
-50000
CY2024Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1458000
CY2023Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1674000
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4315000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3592000
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
5773000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
5266000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5787000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5316000
CY2024Q1 erna Warrant Liabilities Expense
WarrantLiabilitiesExpense
70000
CY2023Q1 erna Warrant Liabilities Expense
WarrantLiabilitiesExpense
45000
CY2024Q1 erna Loss On Non Controlling Investment
LossOnNonControllingInvestment
0
CY2023Q1 erna Loss On Non Controlling Investment
LossOnNonControllingInvestment
51000
CY2024Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-786000
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1000
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-856000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-95000
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6643000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5411000
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-6647000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5416000
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.23
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.23
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.06
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.06
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5410000
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5410000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5127000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5127000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
2233000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
755000
CY2024Q1 erna Adjustments To Additional Paid In Capital Warrant Issuance Cost
AdjustmentsToAdditionalPaidInCapitalWarrantIssuanceCost
-35000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
282000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-6647000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-3412000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
12107000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
689000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5416000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
7380000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-6647000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5416000
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
39000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
21000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
282000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
689000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
502000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
41000
CY2024Q1 erna Gain Loss On Disposal Of Fixed Assets
GainLossOnDisposalOfFixedAssets
-2000
CY2023Q1 erna Gain Loss On Disposal Of Fixed Assets
GainLossOnDisposalOfFixedAssets
0
CY2024Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
407000
CY2023Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
0
CY2024Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
177000
CY2023Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
0
CY2024Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
445000
CY2023Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
0
CY2024Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
70000
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
45000
CY2024Q1 erna Loss On Non Controlling Investment
LossOnNonControllingInvestment
0
CY2023Q1 erna Loss On Non Controlling Investment
LossOnNonControllingInvestment
51000
CY2024Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-74000
CY2023Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-304000
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-807000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-813000
CY2024Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
108000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
461000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1766000
CY2024Q1 erna Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
123000
CY2023Q1 erna Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-173000
CY2024Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-437000
CY2023Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-438000
CY2024Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-48000
CY2023Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
250000
CY2024Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
0
CY2023Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-362000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3747000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6049000
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
101000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
CY2024Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
4000
CY2023Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-97000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
CY2024Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1405000
CY2023Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0
CY2024Q1 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
20000
CY2023Q1 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
0
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1385000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2459000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-6049000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11670000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15541000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9211000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9492000
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
0
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
1000
CY2024Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2024Q1 erna Warrants Issued
WarrantsIssued
755000
CY2023Q1 erna Warrants Issued
WarrantsIssued
0
CY2024Q1 erna Unpaid Fees Incurred In Connection With The Issuance Of Convertible Notes And Warrants
UnpaidFeesIncurredInConnectionWithTheIssuanceOfConvertibleNotesAndWarrants
46000
CY2023Q1 erna Unpaid Fees Incurred In Connection With The Issuance Of Convertible Notes And Warrants
UnpaidFeesIncurredInConnectionWithTheIssuanceOfConvertibleNotesAndWarrants
0
CY2024Q1 erna Paid In Kind Interest Added To Convertible Notes Principal
PaidInKindInterestAddedToConvertibleNotesPrincipal
177000
CY2023Q1 erna Paid In Kind Interest Added To Convertible Notes Principal
PaidInKindInterestAddedToConvertibleNotesPrincipal
0
CY2024Q1 erna Adjustment To Lease Liability And Right Of Use Asset Due To Remeasurement
AdjustmentToLeaseLiabilityAndRightOfUseAssetDueToRemeasurement
4245000
CY2023Q1 erna Adjustment To Lease Liability And Right Of Use Asset Due To Remeasurement
AdjustmentToLeaseLiabilityAndRightOfUseAssetDueToRemeasurement
0
CY2024Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
279000
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5116000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5397000
CY2024Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
4095000
CY2023Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
4095000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9211000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9492000
CY2024Q1 erna Number Of In Licensed Portfolio Patents
NumberOfInLicensedPortfolioPatents
100
CY2024Q1 us-gaap Cash
Cash
5100000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-193600000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-6600000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3700000
CY2022Q4 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
45500
CY2022Q4 us-gaap Line Of Credit
LineOfCredit
4100000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
4100000
CY2023Q1 erna Proceeds From Option And License Agreement
ProceedsFromOptionAndLicenseAgreement
300000
CY2024Q1 erna Proceeds From Cell Line Customization Activities
ProceedsFromCellLineCustomizationActivities
400000
CY2023Q1 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
1
CY2024Q1 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0
CY2024Q1 us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Modification Of Contract
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract
0
CY2023Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
0
CY2024Q1 erna Option Fee Obligation Payment Percentage
OptionFeeObligationPaymentPercentage
0.20
CY2023Q1 erna Proceeds From Option And License Agreement
ProceedsFromOptionAndLicenseAgreement
300000
CY2024Q1 erna License Costs
LicenseCosts
0
CY2024Q1 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
3785000
CY2024Q1 erna Allocation Percentage Of Fair Value
AllocationPercentageOfFairValue
1
CY2024Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1405000
CY2024Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
66000
CY2024Q1 erna Proceeds From Convertible Debt Net
ProceedsFromConvertibleDebtNet
1339000
CY2024Q1 erna Unpaid Out Of Pocket Costs Tenant Improvement Allowance
UnpaidOutOfPocketCostsTenantImprovementAllowance
600000
CY2023 erna Operating Lease Incremental Borrowing Rate
OperatingLeaseIncrementalBorrowingRate
0.144
CY2024Q1 erna Operating Lease Incremental Borrowing Rate
OperatingLeaseIncrementalBorrowingRate
0.111
CY2024Q1 erna Adjustment To Lease Liability And Right Of Use Asset Due To Remeasurement
AdjustmentToLeaseLiabilityAndRightOfUseAssetDueToRemeasurement
4200000
CY2024Q1 erna Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
0
CY2024Q1 us-gaap Goodwill
Goodwill
2000000
CY2024Q1 erna Out Of Pocket Expenses
OutOfPocketExpenses
400000
CY2024Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
1637000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
68000
CY2024Q1 us-gaap Sublease Income
SubleaseIncome
21000
CY2023Q1 us-gaap Sublease Income
SubleaseIncome
21000
CY2024Q1 us-gaap Variable Lease Cost
VariableLeaseCost
330000
CY2023Q1 us-gaap Variable Lease Cost
VariableLeaseCost
5000
CY2024Q1 us-gaap Lease Cost
LeaseCost
1946000
CY2023Q1 us-gaap Lease Cost
LeaseCost
52000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
32781000
CY2024Q1 erna Adjustment To Remeasurement Of Operating Lease Rou Assets
AdjustmentToRemeasurementOfOperatingLeaseROUAssets
4245000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
502000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
36524000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
35070000
CY2024Q1 erna Adjustment To Lease Liability Due To Remeasurement Of Sublease
AdjustmentToLeaseLiabilityDueToRemeasurementOfSublease
4245000
CY2024Q1 erna Accretion Of Interest Sublease
AccretionOfInterestSublease
709000
CY2024Q1 erna Principal Payments On Operating Lease Liabilities
PrincipalPaymentsOnOperatingLeaseLiabilities
585000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
39439000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
36565000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2874000
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y6M
CY2024Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1107
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
5532000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
6075000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
6238000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
6308000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
6406000
CY2024Q1 erna Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
33880000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
64439000
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
25000000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
39439000
CY2024Q1 us-gaap Interest Payable Current
InterestPayableCurrent
407000
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
176000
CY2024Q1 erna Accrued Legal Fees And Related Current
AccruedLegalFeesAndRelatedCurrent
259000
CY2023Q4 erna Accrued Legal Fees And Related Current
AccruedLegalFeesAndRelatedCurrent
643000
CY2024Q1 erna Accrued Somerville Facility Current
AccruedSomervilleFacilityCurrent
221000
CY2023Q4 erna Accrued Somerville Facility Current
AccruedSomervilleFacilityCurrent
218000
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
218000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
239000
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
201000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
109000
CY2024Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
562000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
508000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1868000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1893000
CY2024Q1 erna License Agreement Automatic Renewal Term
LicenseAgreementAutomaticRenewalTerm
P5Y
CY2023Q1 erna Percentage Of Sublicense Fees Paid Before License Expiration Date
PercentageOfSublicenseFeesPaidBeforeLicenseExpirationDate
0.20
CY2023Q1 erna Related Party Transaction Periodic Fees Payment Amount
RelatedPartyTransactionPeriodicFeesPaymentAmount
400000
CY2024Q1 erna Notice Period For First Termination Of Contract
NoticePeriodForFirstTerminationOfContract
P120D
CY2022Q4 erna Payment Of Option Fee
PaymentOfOptionFee
250000
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
282000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
689000
CY2024Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
20386
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
30436000
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5281000
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false

Files In Submission

Name View Source Status
erna-20240331_cal.xml Edgar Link unprocessable
erna-20240331_def.xml Edgar Link unprocessable
0001140361-24-026010-index-headers.html Edgar Link pending
0001140361-24-026010-index.html Edgar Link pending
0001140361-24-026010.txt Edgar Link pending
0001140361-24-026010-xbrl.zip Edgar Link pending
ef20026296_10q.htm Edgar Link pending
ef20026296_10q_htm.xml Edgar Link completed
ef20026296_ex31-1.htm Edgar Link pending
ef20026296_ex31-2.htm Edgar Link pending
ef20026296_ex32-1.htm Edgar Link pending
ef20026296_ex32-2.htm Edgar Link pending
erna-20240331.xsd Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image00007.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
erna-20240331_lab.xml Edgar Link unprocessable
erna-20240331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending